Repare Therapeutics Inc.
Clinical‑stage oncology biotech leveraging its CRISPR‑enabled SNIPRx platform to target DNA‑damage‑repair defects with oral inhibitors RP‑3500 and RP‑6306 in Phase 1/2 trials; supported by Roche, BMS, and Debiopharm collaborations from its Montreal base.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Professional Services
- Industry: Biotechnology Research
- Employees: 129
- HQ: Montreal
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.